Hodgkin Lymphoma News and Research

RSS
Xencor, MorphoSys initiate XmAb5574 Phase 1 study in CLL

Xencor, MorphoSys initiate XmAb5574 Phase 1 study in CLL

Pfizer to present data on hematology portfolio at ASH Annual Meeting

Pfizer to present data on hematology portfolio at ASH Annual Meeting

ASH to host annual meeting for blood disorders at Orange Convention Center

ASH to host annual meeting for blood disorders at Orange Convention Center

Initial data from resminostat Phase II Hodgkin Lymphoma trial to be presented at 52nd ASH

Initial data from resminostat Phase II Hodgkin Lymphoma trial to be presented at 52nd ASH

Results of pixantrone phase III trial for non-Hodgkin's lymphoma to be presented at Hematology Meeting

Results of pixantrone phase III trial for non-Hodgkin's lymphoma to be presented at Hematology Meeting

Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting

Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting

CDC data: Adults remain unvaccinated against preventable infectious illnesses

CDC data: Adults remain unvaccinated against preventable infectious illnesses

New technique to identify cancer biomarkers

New technique to identify cancer biomarkers

EMA reviews CTI's Pixuvri Marketing Authorization Application for NHL

EMA reviews CTI's Pixuvri Marketing Authorization Application for NHL

EMA approves CTI's Pixuvri Pediatric Investigation Plan for lymphoid malignancies and solid tumors

EMA approves CTI's Pixuvri Pediatric Investigation Plan for lymphoid malignancies and solid tumors

4SC to present development of resminostat and preclinical drug candidates at EORTC-NCI-AACR symposium

4SC to present development of resminostat and preclinical drug candidates at EORTC-NCI-AACR symposium

Spectrum Pharmaceuticals to present ZEVALIN data at ASH Meeting

Spectrum Pharmaceuticals to present ZEVALIN data at ASH Meeting

BioWorld Today features ImmunGene's pipeline of next generation armed antibodies for cancer

BioWorld Today features ImmunGene's pipeline of next generation armed antibodies for cancer

4SC 2010 first nine months revenue decreases from EUR1.4 million to EUR0.8 million

4SC 2010 first nine months revenue decreases from EUR1.4 million to EUR0.8 million

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

TRU-016 abstracts to be presented at ASH meeting

TRU-016 abstracts to be presented at ASH meeting

Long-term use of statins unlikely to substantially increase overall cancer risk: Study

Long-term use of statins unlikely to substantially increase overall cancer risk: Study

Patients with germinal center-like structures face greater risk of developing non-Hodgkin's lymphoma

Patients with germinal center-like structures face greater risk of developing non-Hodgkin's lymphoma

Seattle Genetics, Millennium to feature SGN-35 in two oral presentations at ASH Annual Meeting

Seattle Genetics, Millennium to feature SGN-35 in two oral presentations at ASH Annual Meeting

People with SLE more likely to develop hematologic malignancies

People with SLE more likely to develop hematologic malignancies

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.